{"title":"动脉粥样硬化局部免疫调节的新药物递送策略","authors":"Caleb Nunes, Amelia Kramer, Lisa R. Volpatti","doi":"10.1016/j.jconrel.2025.114261","DOIUrl":null,"url":null,"abstract":"Atherosclerosis is a leading cause of cardiovascular disease, which is responsible for one in three deaths globally. Characterized by the blocking of arteries, atherosclerosis develops when lipids accumulate in arterial walls and harden into a plaque. When macrophages consume excess modified low-density lipoprotein, they become inflamed and transform into foam cells, which further contribute to plaque development. The standard-of-care for atherosclerosis treatment includes diet and exercise and lipid-lowering therapies such as statins that do not fully address the inflammation that underlies the disease. While many anti-inflammatory therapies have shown promise in vitro and in vivo, their clinical translation has been limited by poor selectivity and off-target effects. This review explores emerging drug delivery strategies designed to improve the precision of anti-inflammatory treatments for atherosclerosis. We highlight nanoparticle-based approaches constructed from lipids, polymers, polysaccharides, metals, and two-dimensional materials, alongside biologic platforms that leverage cell membranes, extracellular vesicles, viruses, and engineered proteins. Finally, we discuss key challenges and considerations for translating these technologies into clinically viable therapies.","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"31 1","pages":""},"PeriodicalIF":11.5000,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emerging drug delivery strategies for local immunomodulation in atherosclerosis\",\"authors\":\"Caleb Nunes, Amelia Kramer, Lisa R. Volpatti\",\"doi\":\"10.1016/j.jconrel.2025.114261\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Atherosclerosis is a leading cause of cardiovascular disease, which is responsible for one in three deaths globally. Characterized by the blocking of arteries, atherosclerosis develops when lipids accumulate in arterial walls and harden into a plaque. When macrophages consume excess modified low-density lipoprotein, they become inflamed and transform into foam cells, which further contribute to plaque development. The standard-of-care for atherosclerosis treatment includes diet and exercise and lipid-lowering therapies such as statins that do not fully address the inflammation that underlies the disease. While many anti-inflammatory therapies have shown promise in vitro and in vivo, their clinical translation has been limited by poor selectivity and off-target effects. This review explores emerging drug delivery strategies designed to improve the precision of anti-inflammatory treatments for atherosclerosis. We highlight nanoparticle-based approaches constructed from lipids, polymers, polysaccharides, metals, and two-dimensional materials, alongside biologic platforms that leverage cell membranes, extracellular vesicles, viruses, and engineered proteins. Finally, we discuss key challenges and considerations for translating these technologies into clinically viable therapies.\",\"PeriodicalId\":15450,\"journal\":{\"name\":\"Journal of Controlled Release\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":11.5000,\"publicationDate\":\"2025-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Controlled Release\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jconrel.2025.114261\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jconrel.2025.114261","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Emerging drug delivery strategies for local immunomodulation in atherosclerosis
Atherosclerosis is a leading cause of cardiovascular disease, which is responsible for one in three deaths globally. Characterized by the blocking of arteries, atherosclerosis develops when lipids accumulate in arterial walls and harden into a plaque. When macrophages consume excess modified low-density lipoprotein, they become inflamed and transform into foam cells, which further contribute to plaque development. The standard-of-care for atherosclerosis treatment includes diet and exercise and lipid-lowering therapies such as statins that do not fully address the inflammation that underlies the disease. While many anti-inflammatory therapies have shown promise in vitro and in vivo, their clinical translation has been limited by poor selectivity and off-target effects. This review explores emerging drug delivery strategies designed to improve the precision of anti-inflammatory treatments for atherosclerosis. We highlight nanoparticle-based approaches constructed from lipids, polymers, polysaccharides, metals, and two-dimensional materials, alongside biologic platforms that leverage cell membranes, extracellular vesicles, viruses, and engineered proteins. Finally, we discuss key challenges and considerations for translating these technologies into clinically viable therapies.
期刊介绍:
The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System.
Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.
Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.